Table 3.
Baseline characteristics of patients in BCLC stage B-C after PSM
| Variable | RR (11) | TACE (11) | P | RFA (24) | TACE (24) | P |
|---|---|---|---|---|---|---|
| Age (years) | 0.647 | 0.439 | ||||
| ≤60 | 8 (72.7) | 7 (63.6) | 19 (79.2) | 21 (87.5) | ||
| >60 | 3 (27.3) | 4 (36.4) | 5 (20.8) | 3 (12.5) | ||
| Gender | 1.000 | 0.477 | ||||
| Male | 10 (90.9) | 10 (90.9) | 18 (75.0) | 20 (83.3) | ||
| Female | 1 (9.1) | 1 (9.1) | 6 (25.0) | 4 (16.7) | ||
| Hemoglobin (g/L) | 1.000 | 0.439 | ||||
| ≤120 | 0 (0.0) | 0 (0.0) | 5 (20.8) | 3 (12.5) | ||
| >120 | 11(100.0) | 11(100.0) | 19 (79.2) | 21 (87.5) | ||
| Albumin (g/L) | 1.000 | 0.298 | ||||
| ≤35 | 2 (18.2) | 2 (18.2) | 1 (4.2) | 3 (12.5) | ||
| >35 | 9 (81.8) | 9 (81.8) | 23 (95.8) | 21 (87.5) | ||
| Total bilirubin (mmol/L) | 1.000 | 1.000 | ||||
| ≤34.2 | 11(100.0) | 11(100.0) | 23 (95.8) | 23 (95.8) | ||
| >34.2 | 0 (0.0) | 0 (0.0) | 1 (4.2) | 1 (4.2) | ||
| ALT (U/L) | 1.000 | 0.731 | ||||
| ≤40 | 8 (72.7) | 8 (72.7) | 18 (75.0) | 19 (79.2) | ||
| >40 | 3 (27.3) | 3 (27.3) | 6 (25.0) | 5 (20.8) | ||
| AST (U/L) | 0.647 | 0.745 | ||||
| ≤40 | 7 (63.6) | 8 (72.7) | 17 (70.8) | 18 (75.0) | ||
| >40 | 4 (36.4) | 3 (27.3) | 7 (29.2) | 6 (25.0) | ||
| GGT (U/L) | 1.000 | 0.074 | ||||
| ≤50 | 7 (63.6) | 7 (63.6) | 12 (50.0) | 18 (75.0) | ||
| >50 | 4 (36.4) | 4 (36.4) | 12 (50.0) | 6 (25.0) | ||
| PT (s) | 1.000 | 1.000 | ||||
| ≤14 | 10 (90.9) | 10 (90.9) | 24 (100.0) | 24 (100.0) | ||
| >14 | 1 (9.1) | 1 (9.1) | 0 (0.0) | 0 (0.0) | ||
| HBV positive | 11(100.0) | 9 (81.8) | 0.138 | 21 (87.5) | 22 (91.7) | 0.637 |
| HCV positive | 0 (0.0) | 0 (0.0) | 1.000 | 0 (0.0) | 2 (8.3) | 0.149 |
| BCLC stage of primary tumor | 0.665 | 0.773 | ||||
| 0-A | 5 (45.5) | 4 (36.4) | 11 (45.8) | 12 (50.0) | ||
| B-C | 6 (54.5) | 7 (63.6) | 13 (54.2) | 12 (50.0) | ||
| Platelet (×109/L) | 1.000 | 0.637 | ||||
| ≤100 | 0 (0.0) | 0 (0.0) | 2 (8.3) | 3 (12.5) | ||
| >100 | 11(100.0) | 11(100.0) | 2 (91.7) | 21 (87.5) | ||
| AFP (ug/L) | 1.000 | 0.525 | ||||
| ≤200 | 6 (54.5) | 6 (54.5) | 16 (66.7) | 18 (75.0) | ||
| >200 | 5 (45.5) | 5 (45.5) | 8 (33.3) | 6 (25.0) | ||
| Child-Pugh classification | 1.000 | 1.000 | ||||
| Child-Pugh A | 11(100.0) | 11(100.0) | 24 (100.0) | 24 (100.0) | ||
| Child-Pugh B | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| Tumor size (cm) | 0.647 | 1.000 | ||||
| ≤5 | 8 (72.7) | 7 (63.6) | 23 (95.8) | 23 (95.8) | ||
| >5 | 3 (27.3) | 4 (36.4) | 1 (4.2) | 1 (4.2) | ||
| Macrovascular invasion | 3 (27.3) | 5 (45.5) | 0.375 | 2 (8.3) | 2 (8.3) | 1.000 |
| TTR | 0.611 | 0.551 | ||||
| <1 year | 8 (72.7) | 9 (81.8) | 23 (95.8) | 22 (91.7) | ||
| ≥1 year | 3 (27.3) | 2 (18.2) | 1 (4.2) | 2 (8.3) |
Abbreviations: PSM (propensity score matching), ALT (alanine transaminase), AST (aspartate aminotransferase), GGT (glutamyl transpeptidase), PT (prothrombin time), HBV (hepatitis B virus), AFP (alpha fetal protein), TTR (time to recurrence).